Literature DB >> 12873990

Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.

Alexis Gorden1, Iman Osman, Weiming Gai, Dan He, Weiqing Huang, Anne Davidson, Alan N Houghton, Klaus Busam, David Polsky.   

Abstract

We examined mutations in BRAF exons 11 and 15 and N-RAS exons 2 and 3, in 77 metastatic melanoma cases and 11 melanoma cell lines. Significant differences in the mutation rates observed at different metastatic sites could not be detected. The most frequent mutation, the V599E amino acid substitution in BRAF exon 15, was observed in 31 of 77 (40%) tissues and 5 of 11 (45%) cell lines. Tandem base-pair substitutions encoding V599R and V599K amino acid changes were observed in two cases. Novel findings with respect to melanoma include a cell line possessing a 2 base-pair substitution in BRAF exon 11 and a case harboring mutations in both BRAF exon 11 and N-RAS exon 3. Our data show that BRAF mutation is common in melanoma metastases, regardless of their site, that mutations include both exons 11 and 15, and suggest that anti-RAS/RAF strategies may be effective in metastatic melanoma patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12873990

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

Review 1.  Melanocyte receptors: clinical implications and therapeutic relevance.

Authors:  J Andrew Carlson; Gerald P Linette; Andrew Aplin; Bernard Ng; Andrzej Slominski
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

Review 2.  Advances in cutaneous melanoma.

Authors:  Enrique Espinosa; Alfonso Berrocal; José Antonio López Martín; María González Cao; Pablo Cerezuela; José Ignacio Mayordomo; Salvador Martín Algarra
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

Review 3.  Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.

Authors:  Christine A Pratilas; David B Solit
Journal:  Clin Cancer Res       Date:  2010-05-14       Impact factor: 12.531

4.  Targeting oncogenic BRAF in human cancer.

Authors:  Christine A Pratilas; Feng Xing; David B Solit
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

5.  BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer.

Authors:  Kuo-Hsing Chen; Yu-Lin Lin; Jau-Yu Liau; Jia-Huei Tsai; Li-Hui Tseng; Liang-In Lin; Jin-Tung Liang; Been-Ren Lin; Ji-Shiang Hung; Yih-Leong Chang; Kun-Huei Yeh; Ann-Lii Cheng
Journal:  Med Oncol       Date:  2016-03-31       Impact factor: 3.064

6.  Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.

Authors:  Shile Liang; Arati Sharma; Hsin-Hsin Peng; Gavin Robertson; Cheng Dong
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

Review 7.  Chemoprevention of melanoma.

Authors:  Marie-France Demierre; Glenn Merlino
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

8.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Authors:  Moriah H Nissan; Christine A Pratilas; Alexis M Jones; Ricardo Ramirez; Helen Won; Cailian Liu; Shakuntala Tiwari; Li Kong; Aphrothiti J Hanrahan; Zhan Yao; Taha Merghoub; Antoni Ribas; Paul B Chapman; Rona Yaeger; Barry S Taylor; Nikolaus Schultz; Michael F Berger; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2014-02-27       Impact factor: 12.701

9.  Rewired ERK-JNK signaling pathways in melanoma.

Authors:  Pablo Lopez-Bergami; Conway Huang; James S Goydos; Dana Yip; Menashe Bar-Eli; Meenhard Herlyn; Keiran S M Smalley; Alka Mahale; Alexey Eroshkin; Stuart Aaronson; Ze'ev Ronai
Journal:  Cancer Cell       Date:  2007-05       Impact factor: 31.743

10.  Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Authors:  Anton Platz; Suzanne Egyhazi; Ulrik Ringborg; Johan Hansson
Journal:  Mol Oncol       Date:  2007-12-28       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.